Shuwen Biotech Collaborates with PerkinElmer to Offer Breakthrough Preeclampsia Detection Device Globally 

Shuwen Biotech Co Ltd, a China-based leader in innovative diagnostics announced that PerkinElmer, Inc will distribute Shuwen’s breakthrough diagnostic test for preeclampsia in over 100 countries around the globe, accounting for over 120 million pregnancies annually.

Shuwen's breakthrough preeclampsia detection kit is a highly accurate, urine-based, non-invasive point-of-care test, meaning no specialised instrumentation or equipment is needed to operate the test. The test is cost-effective, produces a result in less than three minutes and is currently available for sale in a number of markets. Clinical testing has shown the test to be over 95% accurate in diagnosing preeclampsia in women who are admitted to hospitals, regardless of reason for admission.

“PerkinElmer is committed to improving the lives of pregnant women and children globally, and this relationship helps us leverage our strong scientific and commercial network to offer Shuwen's innovative product to more women in need all over the world,” said Petra Furu, PhD, General Manager, Reproductive Health, PerkinElmer. “There is a global need for advanced diagnostic solutions for, and we believe this point-of-care test will help address this need with respect to preeclampsia."

Shuwen’s Chairman and CEO, Jay Z. Zhang, M.S., J.D., added: “Shuwen's core values are innovation, patent protection and international collaboration, and I am happy to see all three of these values are being realised through our collaboration with PerkinElmer. We are now able to expand the impact of our life-improving products to an unprecedented global scale. PerkinElmer has a strong track record of commitment to maternal foetal health globally and we are proud to be working together."